![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAGEA12 |
Gene summary for MAGEA12 |
![]() |
Gene information | Species | Human | Gene symbol | MAGEA12 | Gene ID | 4111 |
Gene name | MAGE family member A12 | |
Gene Alias | CT1.12 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P43365 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4111 | MAGEA12 | S014 | Human | Liver | HCC | 1.02e-48 | 1.23e+00 | 0.2254 |
4111 | MAGEA12 | S015 | Human | Liver | HCC | 1.99e-43 | 1.45e+00 | 0.2375 |
4111 | MAGEA12 | S016 | Human | Liver | HCC | 2.45e-59 | 1.32e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEA12 | SNV | Missense_Mutation | c.688N>A | p.Ala230Thr | p.A230T | P43365 | protein_coding | deleterious(0) | benign(0.122) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGEA12 | SNV | Missense_Mutation | c.582N>C | p.Gln194His | p.Q194H | P43365 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAGEA12 | SNV | Missense_Mutation | novel | c.298N>C | p.Asp100His | p.D100H | P43365 | protein_coding | deleterious(0.02) | possibly_damaging(0.873) | TCGA-AC-A3TM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
MAGEA12 | SNV | Missense_Mutation | novel | c.929N>C | p.Arg310Thr | p.R310T | P43365 | protein_coding | deleterious(0) | possibly_damaging(0.529) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
MAGEA12 | SNV | Missense_Mutation | c.650N>A | p.Pro217His | p.P217H | P43365 | protein_coding | deleterious(0.03) | benign(0.135) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAGEA12 | SNV | Missense_Mutation | novel | c.512N>A | p.Arg171His | p.R171H | P43365 | protein_coding | deleterious(0) | possibly_damaging(0.501) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MAGEA12 | SNV | Missense_Mutation | c.115N>T | p.Ala39Ser | p.A39S | P43365 | protein_coding | tolerated(0.56) | possibly_damaging(0.897) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD | |
MAGEA12 | SNV | Missense_Mutation | c.271N>C | p.Glu91Gln | p.E91Q | P43365 | protein_coding | tolerated(0.07) | possibly_damaging(0.883) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
MAGEA12 | SNV | Missense_Mutation | c.376N>T | p.Ala126Ser | p.A126S | P43365 | protein_coding | tolerated(0.12) | benign(0.164) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
MAGEA12 | SNV | Missense_Mutation | c.663N>G | p.Ile221Met | p.I221M | P43365 | protein_coding | tolerated(0.1) | benign(0.292) | TCGA-EW-A1P5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4111 | MAGEA12 | NA | vaccine | MAGE-12 PEPTIDE VACCINE |
Page: 1 |